Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma

Photodermatology Photoimmunology and Photomedicine

Volumn 22, Issue 5, 2006, Pages 254-258

  Zane, Cristina ^a   Venturini, Maria ^a   Sala, Raffaella ^a   Calzavara Pinton, Piergiacomo ^a  

^a Spedali Civili ^*  (Italy)

Author keywords

Cutaneous T cell lymphoma; Methylaminolevulinate; Mycosis fungoides; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; PSORALEN; STEROID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOCHEMISTRY; LIGHT IRRADIANCE; MALE; MYCOSIS FUNGOIDES; PAIN ASSESSMENT; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PUVA; RED LIGHT; SKIN BIOPSY; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR REGRESSION; ULTRAVIOLET A RADIATION; VISUAL ANALOG SCALE;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AMINOLEVULINIC ACID; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33748280665     PISSN: 09054383     EISSN: 16000781     Source Type: Journal    
DOI: 10.1111/j.1600-0781.2006.00246.x     Document Type: Article

References (22)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Heald PW, Glusac EJ. Unilesional cutaneous T-cell lymphoma: Clinical features, therapy, and follow-up of 10 patients with a treatment responsive mycosis fungoides variant. J Am Acad Dermatol 2000; 42: 283-285.
3. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: Results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-232.
4. Foley P, Freeman M, Siller G, et al. A phase III randomised study comparing photodynamic therapy (PDT) using methyl aminolevulinate or placebo cream in nodular basal cell carcinoma (NBCC). J Eur Acad Dermatol Venereol 2003; 17 (Suppl. 3): 231.
5. Price DD, McGrath PA, Rafii A, Buckingham B. The validation of visual analog scale as ratio scale measures for chronic and experimental pain. Pain 1983; 17: 45-56.
6. Gaullier JM, Berg K, Peng Q, et al. Use of 5 aminolevulinic acid esters to improve photodynamic therapy on cells in culture. Cancer Res 1997; 57: 1481-1486.
7. Grebenova D, Cajthamlova H, Bartosova J, et al. Selective destruction of leukaemic cells by photo-activation of 5-aminolaevulinic acid-induced protoporphyrin-IX. J Photochem Photobiol B 1998; 47: 74-81.
8. Deahl JT, Oleinick NL, Evans HH. Large mutagenic lesions are induced by photodynamic therapy in murine LS5178Y lymphoblasts. Photochem Photobiol 1993; 58: 259-264.
9. Leibovici L, Schoenfeld N, Yehoshua HA, et al. Activity of porphobilinogen deaminase in peripheral blood mononuclear cells of patients with metastatic cancer. Cancer 1988; 62: 2297-2300.
10. Lopez RFV, Lange N, Guy R, Lopes Badra Bentley MV. Photodynamic therapy of skin cancer: Controlled drug delivery of 5-ALA and its esters. Adv Drug Del Rev 2004; 56: 77-94.
11. Dailey HA, Smith A. Differential interaction of porphyrins used in photoradiation therapy with ferrochelatase. Biochem J 1984; 223: 441-445.
12. Oseroff AR, Hryhorenko E, van Leengoed H, Morgan J, Rittenhose-Diakun K. Intracellular iron levels regulate ALA-induced protoporphyrin IX accumulation in activated and malignant lymphocytes: Implications for selective therapies. J Invest Dermatol 1995; 104: 575.
13. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994; 130: 743-751.
14. Orestein A, Haik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg 2000; 26: 765-769.
15. Peng Q, Soler AM, Warloe T, et al. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001; 71: 640-647.
16. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994; 31: 678-680.
17. Ammann R, Hunziker T. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1995; 33: 541.
18. Edstrom DW, Porwit A, Ros AM. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: Clinical and histological response. Acta Derm Venereol 2001; 81: 184-188.
19. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002; 27: 516-518.
20. Markham T, Sheahan K, Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol 2001; 144: 1262-1263.
21. Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T cell lymphoma. J Am Acad Dermatol 2004; 50: 363-367.
22. Vonderheid EC, Bernengo MG. The Sezary syndrome: Hematologic criteria. Hematol Oncol Clin North Am 2003; 17: 1367-1389.